Sionna Therapeutics, Inc. (NASDAQ:SION) Stock Has Average Price Target of $42.33 According to Brokerages

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) have been assigned an average recommendation of “Hold” from the thirteen research firms that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, eleven have given a hold recommendation and one has issued a buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $42.33.

A number of analysts have recently issued reports on the stock. Citigroup downgraded shares of Sionna Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, August 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Sionna Therapeutics in a report on Wednesday, August 5th. JonesTrading lowered Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 10th. Lifesci Capital cut Sionna Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 10th. Finally, Wall Street Zen downgraded Sionna Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 15th.

Insider Activity

In related news, Director Ra Capital Management, L.P. sold 3,448,811 shares of the firm’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $6.33, for a total transaction of $21,830,973.63. Following the completion of the sale, the director directly owned 3,448,812 shares of the company’s stock, valued at approximately $21,830,979.96. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Sionna Therapeutics in the 2nd quarter worth approximately $64,875,000. Candriam S.C.A. purchased a new position in shares of Sionna Therapeutics during the 1st quarter worth approximately $9,494,000. Eventide Asset Management LLC acquired a new stake in Sionna Therapeutics in the 4th quarter valued at approximately $26,290,000. Artia Global Partners LP acquired a new stake in Sionna Therapeutics in the 4th quarter valued at approximately $4,926,000. Finally, Stempoint Capital LP purchased a new stake in Sionna Therapeutics in the first quarter valued at approximately $1,465,000.

Sionna Therapeutics Stock Performance

Shares of SION opened at $4.90 on Thursday. Sionna Therapeutics has a 12-month low of $4.01 and a 12-month high of $54.97. The firm has a 50-day moving average price of $10.38 and a 200 day moving average price of $30.30. The firm has a market capitalization of $221.53 million, a P/E ratio of -2.25 and a beta of 1.00.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($0.02). Equities research analysts predict that Sionna Therapeutics will post -2.54 earnings per share for the current fiscal year.

Sionna Therapeutics Company Profile

Sionna Therapeutics, Inc (NASDAQ:SION) is a clinical-stage biopharmaceutical company focused on developing treatments for cystic fibrosis (CF), a genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The company is developing small-molecule therapies intended to address the underlying cause of CF by improving the production, processing, stability and function of defective CFTR proteins.

Sionna’s research platform is centered on CFTR modulators, including compounds designed to stabilize the CFTR protein’s nucleotide-binding domain 1 (NBD1).